Disseminated Intravascular Coagulation in Term and Preterm Neonates

ABSTRACT

Among critically ill patients, the risk of developing disseminated intravascular coagulation (DIC) is probably highest in neonates. Low plasma reserves in pro- and anticoagulant coagulation factors, intravascular volume contraction after birth, and a high incidence of hypoxia and sepsis in critically ill newborns rapidly lead to a decompensation of the coagulation system in this population. Global coagulation tests and single-factor plasma levels have to be interpreted in the context of age-corrected normal ranges. Platelet consumption and reduced protein C plasma levels have diagnostic value; the latter also has prognostic potential in neonates with DIC and sepsis. Therapeutic success relies heavily on reversal of the underlying condition. Some coagulation-specific therapies have been explored in small studies and case series with varying success and sometimes conflicting results. Therefore, larger controlled trials in this common and serious condition are urgently needed.

KEYWORDS

Disseminated intravascular coagulation - newborn - preterm - heparin - fresh frozen plasma

REFERENCES

• 1 Bick R L. Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care.  Clin Appl Thromb Hemost. 2002;  8(1) 1-31
• 2 Dairaku M, Sueishi K, Tanaka K. Disseminated intravascular coagulation in newborn infants. Prevalence in autopsies and significance as a cause of death.  Pathol Res Pract. 1982;  174(1-2) 106-115
• 3 Arkhangel'skii A V, Masliakova G N. Frequency and morphology of DIC-syndrome in children in early neonatal period [in Russian].  Arkh Patol. 1996;  58(5) 61-63
• 4 Schmidt B, Vegh P, Johnston M, Andrew M, Weitz J. Do coagulation screening tests detect increased generation of thrombin and plasmin in sick newborn infants?.  Thromb Haemost. 1993;  69(5) 418-421
• 5 Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant.  Am J Pediatr Hematol Oncol. 1990;  12(1) 95-104
• 6 Andrew M, Paes B, Milner R et al.. Development of the human coagulation system in the healthy premature infant.  Blood. 1988;  72(5) 1651-1657
• 7 Bednarek F J, Bean S, Barnard M R, Frelinger A L, Michelson A D. The platelet hyporeactivity of extremely low birth weight neonates is age-dependent.  Thromb Res. 2009;  124(1) 42-45
• 8 Schmugge M, Rand M L, Bang K W et al.. The relationship of von Willebrand factor binding to activated platelets from healthy neonates and adults.  Pediatr Res. 2003;  54(4) 474-479
• 9 Monagle P, Barnes C, Ignjatovic V et al.. Developmental haemostasis. Impact for clinical haemostasis laboratories.  Thromb Haemost. 2006;  95(2) 362-372
• 10 Angus D C, Linde-Zwirble W T, Lidicker J, Clermont G, Carcillo J, Pinsky M R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.  Crit Care Med. 2001;  29(7) 1303-1310
• 11 Watson R S, Carcillo J A, Linde-Zwirble W T, Clermont G, Lidicker J, Angus D C. The epidemiology of severe sepsis in children in the United States.  Am J Respir Crit Care Med. 2003;  167(5) 695-701
• 12 Meadow W, Frain L, Ren Y, Lee G, Soneji S, Lantos J. Serial assessment of mortality in the neonatal intensive care unit by algorithm and intuition: certainty, uncertainty, and informed consent.  Pediatrics. 2002;  109(5) 878-886
• 13 El Beshlawy A, Alaraby I, Abou Hussein H, Abou-Elew H H, Mohamed Abdel Kader M S. Study of protein C, protein S, and antithrombin III in newborns with sepsis.  Pediatr Crit Care Med. 2010;  11(1) 52-59
• 14 Watanabe R, Wada H, Miura Y et al.. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.  Clin Appl Thromb Hemost. 2001;  7(3) 229-233
• 15 Jacobs S, Hunt R, Tarnow-Mordi W, Inder T, Davis P. Cooling for newborns with hypoxic ischaemic encephalopathy.  Cochrane Database Syst Rev. 2007;  (4) CD003311
• 16 Franzoi M, Simioni P, Luni S, Zerbinati P, Girolami A, Zanardo V. Effect of delivery modalities on the physiologic inhibition system of coagulation of the neonate.  Thromb Res. 2002;  105(1) 15-18
• 17 Suzuki S, Morishita S. Hypercoagulability and DIC in high-risk infants.  Semin Thromb Hemost. 1998;  24(5) 463-466
• 18 El Beshlawy A, Hussein H A, Abou-Elew H H, Abdel Kader M S. Study of protein C, protein S, and antithrombin III in hypoxic newborns.  Pediatr Crit Care Med. 2004;  5(2) 163-166
• 19 Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey.  Arch Dis Child Fetal Neonatal Ed. 1997;  76(3) F163-F167
• 20 De Noronha L, Medeiros F, Nones R B et al.. Brain hypoxic-injury of hemorrhagic pattern in newborns: analysis of 1028 autopsies from 1960 to 1995 [in Portuguese].  Arq Neuropsiquiatr. 1999;  57(4) 950-958
• 21 Moodley J, Naidu S, Chetty D, Adhikari M, Gouw E. Neonatal thrombocytopaenia in preeclamptic women with low platelet count.  Hypertens Pregnancy. 1996;  15(3) 297-304
• 22 Fischer D, Schloesser R, Buxmann H, Veldman A. Recombinant activated factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation.  J Pediatr Hematol Oncol. 2008;  30(5) 337-342
• 23 Aronis S, Platokouki H, Photopoulos S, Adamtziki E, Xanthou M. Indications of coagulation and/or fibrinolytic system activation in healthy and sick very-low-birth-weight neonates.  Biol Neonate. 1998;  74(5) 337-344
• 24 Tancabelic J, Haun S E. Management of coagulopathy with recombinant factor VIIa in a neonate with echovirus type 7.  Pediatr Blood Cancer. 2004;  43(2) 170-176
• 25 Kanjanapongkul S, Sangtawesin V. A neonate with petechiae and pancytopenia at birth as uncommon presentation of congenital HIV infection.  J Med Assoc Thai. 2008;  91(suppl 3) S161-S164
• 26 Pearson L, Bissinger R, Romero K R. Neonatal hemochromatosis: a case report.  Adv Neonatal Care. 2009;  9(2) 72-76
• 27 Currie B G, Schell D, Bowring A C. Giant hemangioma of the arm associated with cardiac failure and the Kasabach-Merritt syndrome in a neonate.  J Pediatr Surg. 1991;  26(6) 734-737
• 28 Rohana J, Boo N Y, Hayati A R, Baizura J. Diffuse neonatal haemangiomatosis: a rare cause of haemorrhagic shock and refractory coagulopathy in the newborn.  Med J Malaysia. 2002;  57(3) 364-367
• 29 Branson H E, Katz J, Marble R, Griffin J H. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant.  Lancet. 1983;  2(8360) 1165-1168
• 30 Mahasandana C, Suvatte V, Marlar R A, Manco-Johnson M J, Jacobson L J, Hathaway W E. Neonatal purpura fulminans associated with homozygous protein S deficiency.  Lancet. 1990;  335(8680) 61-62
• 31 Hathaway W E, Mahasandana C, Makowski E L. Cord blood coagulation studies in infants of high-risk pregnant women.  Am J Obstet Gynecol. 1975;  121(1) 51-57
• 32 Göbel U, von Voss H, Jürgens H et al.. Efficiency of heparin in the treatment of newborn infants with respiratory distress syndrome and disseminated intravascular coagulation.  Eur J Pediatr. 1980;  133(1) 47-49
• 33 Culic S. Cold injury syndrome and neurodevelopmental changes in survivors.  Arch Med Res. 2005;  36(5) 532-538
• 34 Zach T L, Cifuentes R F, Strom R L. Congenital mesoblastic nephroma, hemorrhagic shock, and disseminated intravascular coagulation in a newborn infant.  Am J Perinatol. 1991;  8(3) 203-205
• 35 Murphy J J, Blair G K, Fraser G C. Coagulopathy associated with large sacrococcygeal teratomas.  J Pediatr Surg. 1992;  27(10) 1308-1310
• 36 Faxelius G, Teger-Nilsson A C, Wilhelmsson S, Aström L. Disseminated intravascular coagulation and congenital neuroblastoma.  Acta Paediatr Scand. 1975;  64(4) 667-670
• 37 Wan P, Susman J, Kandel J, Jan D, Jerome E H, Parravicini E. Neonatal hepatic mesenchymal hamartoma causing cardiac failure and disseminated intravascular coagulopathy.  Am J Perinatol. 2009;  26(8) 601-604
• 38 Shirahata A, Shirakawa Y, Murakami C. Diagnosis of DIC in very low birth weight infants.  Semin Thromb Hemost. 1998;  24(5) 467-471
• 39 Toh C H, Dennis M. Current clinical practice. DIC 2002: a review of disseminated intravascular coagulation.  Hematology. 2003;  8(2) 65-71
• 40 Shorr A F, Nelson D R, Wyncoll D L et al.. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).  Crit Care. 2008;  12(2) R45
• 41 Kreuz W, Veldmann A, Fischer D, Schlösser R, Volk W R, Ettingshausen C E. Neonatal sepsis: a challenge in hemostaseology.  Semin Thromb Hemost. 1999;  25(6) 531-535
• 42 Lauterbach R, Pawlik D, Radziszewska R, Woźniak J, Rytlewski K. Plasma antithrombin III and protein C levels in early recognition of late-onset sepsis in newborns.  Eur J Pediatr. 2006;  165(9) 585-589
• 43 Ettingshausen C E, Veldmann A, Beeg T, Schneider W, Jäger G, Kreuz W. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans.  Semin Thromb Hemost. 1999;  25(6) 537-541
• 44 Venkataseshan S, Dutta S, Ahluwalia J, Narang A. Low plasma protein C values predict mortality in low birth weight neonates with septicemia.  Pediatr Infect Dis J. 2007;  26(8) 684-688
• 45 Dellinger R P, Levy M M, Carlet J M International Surviving Sepsis Campaign Guidelines Committee et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.  Crit Care Med. 2008;  36(1) 296-327
• 46 Carcillo J A, Fields A I. American College of Critical Care Medicine Task Force Committee Members . Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock.  Crit Care Med. 2002;  30(6) 1365-1378
• 47 Mueller M M, Bomke B, Seifried E. Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases.  Thromb Res. 2002;  107(suppl 1) S9-S17
• 48 Goldenberg N A, Manco-Johnson M J. Pediatric hemostasis and use of plasma components.  Best Pract Res Clin Haematol. 2006;  19(1) 143-155
• 49 Williams M D, Chalmers E A, Gibson B E. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology . The investigation and management of neonatal haemostasis and thrombosis.  Br J Haematol. 2002;  119(2) 295-309
• 50 Saxonhouse M A, Manco-Johnson M J. The evaluation and management of neonatal coagulation disorders.  Semin Perinatol. 2009;  33(1) 52-65
• 51 Stanworth S J, Bennett C. How to tackle bleeding and thrombosis in the newborn.  Early Hum Dev. 2008;  84(8) 507-513
• 52 Gross S J, Filston H C, Anderson J C. Controlled study of treatment for disseminated intravascular coagulation in the neonate.  J Pediatr. 1982;  100(3) 445-448
• 53 Osborn D A, Evans N, Kluckow M. Clinical detection of low upper body blood flow in very premature infants using blood pressure, capillary refill time, and central-peripheral temperature difference.  Arch Dis Child Fetal Neonatal Ed. 2004;  89(2) F168-F173
• 54 Andrew M E, Monagle P, deVeber G, Chan A K. Thromboembolic disease and antithrombotic therapy in newborns.  Hematology Am Soc Hematol Educ Program. 2001;  358-374
• 55 Blauhut B, Necek S, Kramar H, Vinazzer H, Bergmann H. Activity of antithrombin III and effect of heparin on coagulation in shock.  Thromb Res. 1980;  19(6) 775-782
• 56 von Kries R, Stannigel H, Göbel U. Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation.  Eur J Pediatr. 1985;  144(2) 191-194
• 57 Levi M, Toh C H, Thachil J, Watson H G. British Committee for Standards in Haematology . Guidelines for the diagnosis and management of disseminated intravascular coagulation.  Br J Haematol. 2009;  145(1) 24-33
• 58 Eisele B, Lamy M, Thijs L G et al.. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.  Intensive Care Med. 1998;  24(7) 663-672
• 59 Warren B L, Eid A, Singer P KyberSept Trial Study Group et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286(15) 1869-1878
• 60 Wiedermann C J, Hoffmann J N, Juers M KyberSept Investigators et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety.  Crit Care Med. 2006;  34(2) 285-292
• 61 Hoffmann J N, Wiedermann C J, Juers M KyberSept investigators et al. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin.  Thromb Haemost. 2006;  95(5) 850-856
• 62 Wada H, Asakura H, Okamoto K et al.. Expert consensus for the treatment of disseminated intravascular coagulation in Japan.  Thromb Res. 2010;  125(1) 6-11
• 63 Schmidt B, Gillie P, Mitchell L, Andrew M, Caco C, Roberts R. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome.  Am J Respir Crit Care Med. 1998;  158(2) 470-476
• 64 Nowak-Göttl U, Groll A, Kreuz W D et al.. Treatment of disseminated intravascular coagulation with antithrombin III concentrate in children with verified infection [in German].  Klin Padiatr. 1992;  204(3) 134-140
• 65 Yan S B, Helterbrand J D, Hartman D L, Wright T J, Bernard G R. Low levels of protein C are associated with poor outcome in severe sepsis.  Chest. 2001;  120(3) 915-922
• 66 de Kleijn E D, de Groot R, Hack C E et al.. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study.  Crit Care Med. 2003;  31(6) 1839-1847
• 67 Fischer D, Schloesser R L, Nold-Petry C A, Nold M F, Veldman A. Protein C concentrate in preterm neonates with sepsis.  Acta Paediatr. 2009;  98(9) 1526-1529
• 68 Rawicz M, Sitkowska B, Rudzińska I, Kornacka M K, Bocheński P. Recombinant human activated protein C for severe sepsis in a neonate.  Med Sci Monit. 2002;  8(11) CS90-CS94
• 69 Sajan I, Da-Silva S S, Dellinger R P. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.  J Intensive Care Med. 2004;  19(1) 51-55
• 70 Frommhold D, Birle A, Linderkamp O, Zilow E, Pöschl J. Drotrecogin alpha (activated) in neonatal septic shock.  Scand J Infect Dis. 2005;  37(4) 306-308
• 71 Nadel S, Goldstein B, Williams M D Researching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.  Lancet. 2007;  369(9564) 836-843
• 72 Ghosh S, Pendurthi U R, Steinoe A, Esmon C T, Rao L V. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium.  J Biol Chem. 2007;  282(16) 11849-11857
• 73 Lewis N R, Brunker P, Lemire S J, Kaufman R M. Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage.  Transfusion. 2009;  49(4) 689-695
• 74 Kahyaoglu I, Kahyaoglu S, Mollamahmutoglu L. Factor VIIa treatment of DIC as a clinical manifestation of amniotic fluid embolism in a patient with fetal demise.  Arch Gynecol Obstet. 2009;  280(1) 127-129
• 75 Schmid S, Friesenecker B, Lorenz I et al.. Administration of recombinant activated factor VII (NovoSeven) in three cases of uncontrolled bleeding caused by disseminated intravascular coagulopathy.  Clin Appl Thromb Hemost. 2007;  13(3) 313-317
• 76 Zenz W, Zoehrer B, Levin M International Paediatric Meningococcal Thrombolysis Study Group et al. Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study.  Crit Care Med. 2004;  32(8) 1777-1780
• 77 Sawamura A, Hayakawa M, Gando S et al.. Application of the Japanese Association for Acute Medicine disseminated intravascular coagulation diagnostic criteria for patients at an early phase of trauma.  Thromb Res. 2009;  124(6) 706-710
• 78 Kushimoto S, Gando S, Saitoh D Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group et al. Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma.  Thromb Haemost. 2008;  100(6) 1099-1105
• 79 Baslaim G, Bashore J, Al-Malki F, Jamjoom A. Can the outcome of pediatric extracorporeal membrane oxygenation after cardiac surgery be predicted?.  Ann Thorac Cardiovasc Surg. 2006;  12(1) 21-27
• 80 Chiaretti A, Pezzotti P, Mestrovic J et al.. The influence of hemocoagulative disorders on the outcome of children with head injury.  Pediatr Neurosurg. 2001;  34(3) 131-137
• 81 Centers for Disease Control and Prevention (CDC) . Varicella-related deaths among children—United States, 1997.  MMWR Morb Mortal Wkly Rep. 1998;  47(18) 365-368
• 82 El-Nawawy A, Abbassy A A, El-Bordiny M, Essawi S. Evaluation of early detection and management of disseminated intravascular coagulation among Alexandria University pediatric intensive care patients.  J Trop Pediatr. 2004;  50(6) 339-347